SIG pharmaceutical industry to construct Chinese traditional medicine industry chain

SIG Pharmaceutical Co., Ltd. (600518) August 22 held the fifth session of the Board of Directors in 2010, the sixth provisional meeting to consider the adoption of the company's 2010 rights issue proposal.　　It is expected to raise no more than 3.5 billion yuan, committed to the company in the next few years "Kang Mei characteristics" of the construction of Chinese medicine industry chain, trying to obtain the Chinese medicine industry chain production, circulation, retail full profit. The allotment of 10 shares does not exceed 3 shares, is expected to raise the total amount of capital not more than 3.5 billion yuan, all to supplement the production and operation of the necessary operating capital.　　The company will hold a meeting of the provisional Shareholders for consideration on September 8. SIG Pharmaceutical 2009 Sales income of Chinese herbal pieces more than 870 million yuan, production and marketing scale ranked industry first.　　At present, the company has become the Chinese herbal pieces of industry standard-setting participants, has undertaken more than 120 national pieces of quality standard-setting work. In recent years, the company accelerated the pace of integration of Chinese medicine industry chain resources, through strategic investment, active investment and development of raw materials supply, pharmaceutical modern logistics, Chinese herbal medicine market management, medicine and medicine products and medical treatment and other traditional Chinese drugs upstream and downstream industries; At present, it has preliminarily completed the strategic layout in Guangdong, Beijing, Shanghai, Sichuan, Jilin, Anhui and other areas,　　Create conditions for the promotion of business scale. In the next few years, SIG pharmaceutical industry will invest 300 million yuan to build sig (Beijing) Pharmaceutical Co., Ltd. Chinese medicine production base, invest 400 million yuan to construct the northeast ginseng, Chinese herbal medicine product platform, invest 900 million yuan to build three phase expansion project of Chinese herbal pieces, invest 1.5 billion yuan to construct sig (Bozhou) Hua Tuo International Medicine City, etc., the capital demand exceeds 3 billion yuan,　　At present, its own funds still can not meet the capital requirements of the above projects, and as the company's industrial chain integration operations based on the expansion of Chinese herbal medicine business still need a lot of operating capital.　　In the first half of 2010, the company acquired Anhui Bozhou Century Pharmaceutical Co., Ltd. 100% Equity, Bozhou Chinese Herbal Medicine professional market is currently the largest and most powerful distribution of Chinese medicinal herbs professional market, local herbal pieces of annual production in the country's first, medicinal plant area of nearly million acres, Chinese herbal medicine exports ranked the top 3. Through the allocation of shares to the original shareholders into the fund, the company will focus on the core of Chinese herbal pieces, the industrial chain of logistics, capital flow, information flow and other effective integration and use, to large-scale operation of the bulk of Chinese herbal medicines trade, make full use of local medicinal sources and gap planting base resource advantages, Through the logistics distribution system to serve the country-wide downstream customers. Through the middle and lower reaches of Chinese herbal medicines, the company will obtain the full profit of the production, circulation and retailing of the industrial chain.